Investor RelationsFor information regarding Silence's intellectual property portfolio, please visit the Platform Technologies section.
Silence’s Circular April 2013
Silence Therapeutics plc (LSE: SLN) is a global leader in the discovery, development and delivery of novel RNA interference (RNAi) therapeutics for the treatment of serious diseases. The company possesses one of the world’s most comprehensive RNAi therapeutic platforms comprised of proprietary delivery technologies, potent siRNA sequences and innovative siRNA structural features – the three areas the company believes to be critical to building, protecting and commercialising RNAi therapeutics. The Company’s lead internal drug candidate is Atu027, a liposomal formulation in clinical development for systemic cancer indications and one of the most clinically advanced RNAi therapeutic candidates in the area of oncology. Silence’s product portfolio and technology platforms are protected by a strong intellectual property portfolio.
For an updated stock quote, please access the link above to the London Stock Exchange
Capita IRG plc
34 Beckenham Road,
Tel: +44 (0) 871 664 0300
Financial AdvisorsN+1 Singer Capital Markets Limited
One Hanover Street
London, W1S 1YZ
Silence Therapeutics News & Articles on Proactiveinvestors
Silence Therapeutics pleased with Astra collaboration progress
Drug developer Silence Therapeutics ( LON:SLN ) said today its collaboration with pharma giant AstraZeneca...
Silence Therapeutics issues shares to ex-CEO to fulfil contract
Silence Therapeutics ( LON:SLN ) said it is issuing 530,000 new ordinary shares in accordance with a contra...
Silence Therapeutics CEO says he wants to move the stock back towards its high
Thomas Christély, CEO of Silence Therapeutics ( LON:SLN ), explains to Proactive Investors that his strategy...
Silence Therapeutics sees off patent challenge in the US
Silence Therapeutics said the US Patents and Trademark Office has given notice that it will re-issue four pat...
Silence Therapeutics: European Patent Office decision is extremely favourable, says Singer Capital
The European Patent Office's decision to uphold one of Silence Therapeutics ' ( LON:SLN ) key gr...